Indian court dismisses Novartis patent claim

pharmafile | August 8, 2007 | News story | Sales and Marketing India, Novartis 

Novartis has failed in its challenge to India's intellectual property laws as part of its attempt to secure a patent for Glivec in the country.

The company took the Indian government to court over its 2005 Patents Act, claiming it breached World Trade Organisation rules and the Indian constitution.

The High Court in Chennai has deferred to the WTO to resolve the question of compliance with its rules, but dismissed Novartis' petition challenging the constitutionality of the decision not to grant a patent for Glivec.

Novartis said the decision would have "long-term negative consequences for research and development into better medicines for patients in India and abroad".

Novartis India's vice-chairman and managing director Ranjit Shahani said: "We disagree with this ruling; however, we likely will not appeal to the Supreme Court."

Campaigners welcomed the court's decision as a major victory for patient access to affordable medicines in developing countries.

The country is home to some of the world's biggest producers of generics – as well as one of pharma's fastest growing markets – and Medecins Sans Frontieres said the ruling protected India as the pharmacy of the developing world.

Director of the MSF Campaign for Access to Essential Medicines Dr Tido von Schoen-Angerer said: "This is a huge relief for millions of patients and doctors in developing countries who depend on affordable medicines from India.

"The court's decision now makes Indian patents on the medicines that we desperately need less likely."

Novartis provides the cancer drug Glivec free of charge to 99% of patients in India and said its court challenge would not have hindered the supply of medicines from India to poor countries.

 

 

Related Content

Novartis shares new data about Fabhalta for IgAN treatment

Novartis has announced new results from a pre-specified interim analysis of its phase 3 APPLAUSE-IgAN …

chuttersnap-oijvdm3zx4i-unsplash

Novartis shares new data for Zolgensma in children with SMA

Novartis has announced new data to continue the support of the clinical benefits of Zolgensma …

Novartis to acquire MorphoSys AG for €2.7bn

Novartis has announced that it has entered an agreement to acquire MorphoSys AG for €2.7bn, …

Latest content